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Introduction
The mammalian target of rapamycin (mTOR) is a
serine/threonine kinase.1 In response to nutrients, growth fac-
tors, and intracellular energy status, mTOR is activated by
signaling through phosphatidylinositol-3-OH (PI 3) kinase,
PDK1 and Akt.2 mTOR activation leads to phosphorylation of
the translational regulators S6K1 and 4E-BP to regulate pro-
tein synthesis, cell growth, and metabolism, and to cell sur-
vival via phosphorylating Akt on Ser473.2,3
In the hematopoietic system, studies using mTOR inhibitor
rapamycin or its analogs have suggested a role for mTOR in
megakaryocyte and dendritic cell proliferation and differenti-
ation.4,5 Hyper-activation of mTOR by deletion of phos-
phatase and tensin homolog (PTEN) or tuberous sclerosis
complex (TSC), negative regulators of mTOR, results in long-
term hematopoietic stem cell (HSC) exhaustion.6-8 None -
theless, such a gain-of-function approach is not sufficient to
reveal the physiological role of mTOR. Because gene target-
ing of mTOR in embryonic stem cells results in early embry-
onic lethality,9 tissue-specific gene knockout mouse model of
mTOR has recently been generated.10 In the present studies,
we have examined the physiological roles of mTOR in
hematopoiesis and hematopoietic stem cell (HSC) function
by using a hematopoietic-specific inducible mouse knockout
model. We show that mTOR deficiency causes bone marrow
(BM) failure and a markedly decreased production of all blood
lineage cells, as well as impaired HSC engraftment.
Methods
Mice
Conditional gene-targeted mTORloxp/loxp mice were generated as
described previously.9 To delete mTOR in vivo in hematopoietic stem
cells, mTORloxp/loxp;Mx-Cre+mice were generated by breeding mTORloxp/loxp
mice with Mx-Cre+ transgenic mice carrying a bacteriophage Cre
recombinase driven by an interferon-α-inducible Mx1 promoter. The
expression of Cre was induced by 6-8 intraperitoneal (i.p.) injections
of 10 mg/g of body weight polyinosine-polycytidine (pIpC)
(Amersham Pharmacia Biotech, Piscataway, NJ, USA) into the Mx-
Cre+mice at 2-day intervals.
Blood lineage analysis
Single cell suspensions were incubated for 20 min at room temper-
ature with various combinations of the following cell-surface marker
antibodies: PE-Gr1 (clone: RB6-8C5), FITC-Mac1 (clone: M1/70),
FITC-Ter119 (clone: TER-119), PE-CD71 (clone: C2), FITC-B220
(clone: RA3-6B2), Percp-Cy5.5-IgM (clone: G155-228), Percp-Cy5.5-
CD4 (clone: RM4-5), FITC-CD8 (clone: 53-6.7), PE-Cy7-CD150
(clone: TC15-12F12.2), FITC-CD41 (clone: MWReg30), FITC-CD48
(clone: HM48-1), FITC-CD34 (clone: RAM34), PE-Sca1 (clone: D7),
APC-c-Kit (clone: ACK2), PE-Cy7- CD16/CD32 (clone: 93), APC-Cy7-
IL7R (clone: A7R34), PE-H2Kb (clone: AF6-88.5), PE-CD45.1 (clone:
A20), and FITC-CD45.2 (clone: 104). All the antibodies were pur-
chased from BD Biosciences except FITC-CD34, APC-c-Kit, PE-Cy7-
CD16/CD32, and APC-Cy7-IL7R (eBiosciences) and PE-Cy7-CD150
(Biolegend). Immunolabeled cells were analyzed by flow cytometry.
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mTOR integrates signals from nutrients and growth factors to control protein synthesis, cell growth, and survival.
Although mTOR has been established as a therapeutic target in hematologic malignancies, its physiological role
in regulating hematopoiesis remains unclear. Here we show that conditional gene targeting of mTOR causes bone
marrow failure and defects in multi-lineage hematopoiesis including myelopoiesis, erythropoiesis, throm-
bopoiesis, and lymphopoiesis. mTOR deficiency results in loss of quiescence of hematopoietic stem cells, leading
to a transient increase but long-term exhaustion and defective engraftment of hematopoietic stem cells in lethally
irradiated recipient mice.  Furthermore, ablation of mTOR causes increased apoptosis in lineage-committed blood
cells but not hematopoietic stem cells, indicating a differentiation stage-specific function. These results demon-
strate that mTOR is essential for hematopoietic stem cell engraftment and multi-lineage hematopoiesis.
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Colony formation assay
Bone marrow cells (5 x 104 cells) were cultured in 1 mL methyl-
cellulose medium (1% methylcellulose, 30% fetal bovine serum
(FBS), 2% penicillin and streptomycin, 1% bovine serum albumin
(BSA), and 10-4 M b-mercaptoethanol) containing 4 U/mL erythro-
poietin (EPO), 100 ng/mL rrSCF, 100 ng/mL granulocyte-colony
stimulating factor (G-CSF), and 100 ng/mL IL-3 for seven days and
colony-forming unit of multiple myeloid progenitors (CFU-C) and
erythroid burst-forming unit (BFU-E) were counted. For erythroid
CFU (CFU-E) assays, 2 x 105 BM cells were cultured in 1 mL
methylcellulose medium supplemented with 100 ng/mL rrSCF
and 4 U/mL EPO for two days.
Cell cycle and survival analysis
For assessment of cell cycle status of HSCs, mice were given a
single i.p. injection of BrdU (250 mg/kg of body weight). Two
hours later, BM cells were harvested and stained for surface mark-
ers and then fixed and stained with anti-BrdU antibody and 7-
AAD using the Cytofix/Cytoperm Kit (BD Biosciences), according
to the manufacturer's instructions. For survival assays, the apop-
totic cell population was determined by annexin V staining. Cells
were analyzed by flow cytometry.
Quantitative real-time polymerase chain reaction
Total RNA was isolated using RNeasy Micro Kit (Qiagen). First-
strand complementary DNA synthesis was primed with random
hexamers (PE Applied Biosystems) from sample RNA by using the
Sensiscript RT Kit (Qiagen). Real-time quantitative polymerase
chain reaction (PCR) was carried out in an ABI Prism 7700
Sequence Detector using SYBR Green PCR Master Mix reagent
(Applied Biosystems). Primer sequences were: mouse Rb1, for-
ward 5’-atctacctcccttgccctgt-3’, reverse 5’-gaaggcgtgcaca gagtgta-
3’; mouse E2f5, forward 5’-actcagggcctatccatgtg-3’, reverse 5’-
ggggaacaggaaaaaccact-3’; and mouse Mcl1, forward 5’-tgggtttgtg-
gagttcttcc-3’, reverse 5’-aaagccagcagcacatttct-3’.
Transplantation and engraftment assays
Donor BM cells were injected into the tail veins of recipient
mice. For competitive repopulation analysis, donor BM cells were
mixed with recipient BM cells at a 1:1 or 7:3 ratio and injected into
the recipient mice. Chimerism (donor-derived cells) was deter-
mined by FACS analysis of peripheral blood or BM of the recipient
mice after transplantation.
Results
mTOR deficiency causes pancytopenia 
To define the physiological function of mTOR in
hematopoiesis, we deleted mTOR gene in adult
mTORloxp/loxp;Mx1-Cre+ mice by 6-8 i.p. injections of polyi-
nosine-polycytidine (pIpC). Immunoblotting and genotyp-
ing confirmed mTOR deletion in BM cells of the pIpC-
treated mTORloxp/loxp;Mx1-Cre+ (mTOR–/–) mice (Figure 1A).
mTOR–/– mice died 7-17 days after pIpC injection (data not
shown) and the mice were sacrificed for analysis in the
time window. mTOR–/–mice displayed a marked decline in
white blood cell counts (WBC) in peripheral blood, appar-
ently due to reduced number of neutrophils (NE) and
monocytes (MO) (Figure 1B). In addition, the mice
showed a marked reduction in platelets (PLT) and severe
anemia with significantly decreased red blood cells (RBC)
and hemoglobin (Hb) compared to mTOR+/+ controls
(Figure 1B). mTOR deficiency resulted in a 50% loss of
BM cellularity, which was further verified by hematoxylin
and eosin (H&E) staining (Figure 1C). Within the BM, total
myeloid (Gr-1+Mac-1+) cell numbers were drastically
reduced (Figure 1D and Online Supplementary Figure S1A),
and erythroid progenitor differentiation was blocked at
the proerythroblast stage (Figure 1E and Online
Supplementary Figure S1B). B-cell progenitors were also
reduced at all developmental stages (Figure 1F and Online
Supplementary Figure S1C). Within the thymus, mTOR–/–
mice exhibited a defect in T-cell progenitor differentiation
as manifested by a marked reduction in CD4–CD8–,
CD4+CD8+, CD4+, and CD8+ thymocytes (Figure 1G and
Online Supplementary Figure S1D). The defects of mTOR–/–
lineage-committed cells are associated with increased
apoptosis in these cells including myeloid (Figure 1H and
Online Supplementary Figure S1E), erythroid (Figure 1I and
Online Supplementary Figure S1F) and B lineages (Figure 1J
and Online Supplementary Figure S1G). To begin to under-
stand the molecular mechanisms of increased apoptosis in
mTOR–/– lineage-committed cells, we detected the expres-
sion of Mcl-1 and Bcl-xL, two critical pro-survival factors.
mTOR–/– lineage-positive (Lin+) cells displayed a dimin-
ished expression of Mcl-1 but increased level of Bcl-xL
(Figure 1K). It seems that the increased apoptosis in
mTOR–/– lineage-committed cells is due, at least partially, to
decreased Mcl-1, whereas increased Bcl-xL might be a
compensatory effect of increased apoptosis. Taken togeth-
er, mTOR is essential for all hematopoietic lineage devel-
opment.
mTOR regulates HSC and hematopoietic progenitor 
cell homeostasis 
The widespread effect of mTOR deficiency on blood
lineages prompted us to examine the effect of mTOR
knockout on HSCs and hematopoietic progenitor cells
(HPCs). In the HPC compartments, we detected a decrease
in common myeloid progenitors (CMPs) but an increase in
common lymphoid progenitors (CLPs) in mTOR–/– mice
compared to mTOR+/+ controls (Figure 2A and Online
Supplementary Figure S2A). Further analysis revealed that
mTOR deficiency impaired colony-forming ability of
HPCs as shown by markedly reduced activities of BFU-E,
CFU-E, and CFU-C (Figure 2B). In the HSC compartments,
mTOR–/– BM contained approximately 4-fold more primi-
tive LSK (Lin–scal+c-kit+) cells than mTOR+/+ controls (Figure
2C and Online Supplementary Figure S2A). The increased
LSK cells in mTOR–/– BM appeared to stem from an
increase in both short-term (CD34+LSK) and long-term
(CD34–LSK or CD150+CD41–CD48–LSK) HSCs (Figure 2C
and Online Supplementary Figure S2A and B). A BrdU label-
ing assay revealed a 60% increase in mTOR–/–LSK cells at
the S phase (BrdU+) of the cell cycle compared to mTOR+/+
controls (Figure 2D and Online Supplementary Figure S2C)
indicating that mTOR deficiency leads to a loss of HSC
quiescence. Indeed, we found that mTOR deficiency
caused a significant reduction in LSK cells or more primi-
tive CD150+CD41–CD48–LSK cells at the G0 phase (Figure
2E and Online Supplementary Figure S2D). In contrast to the
cell cycle alterations, no difference in apoptosis was
detected between mTOR–/– and mTOR+/+ LSK cells (Figure
2F and Online Supplementary Figure S2E); this is unexpected
given the recognized role of mTOR in regulating cell sur-
vival.2,3 Interestingly,  although mTOR deficiency does not
affect survival status of LSK cells, it increases apoptosis of
more mature blood cell lineages including myeloid and
erythroid cells (Figure 1H and I and Online Supplementary
F. Guo et al.
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Figure S1E and F), suggesting a differentiation stage-specif-
ic role for mTOR. 
To examine the molecular mechanisms related to the
accelerated cell cycle status and the apparently unaltered
survival activity in mTOR–/– HSCs and HPCs, we first ana-
lyzed the activities (phosphorylation) of S6K and 4E-BP
that act downstream of mTOR to promote ribosome bio-
genesis essential for cell growth and survival.2,3 mTOR–/–
Lin- cells had attenuated activities of S6K and 4E-BP in vivo
(Figure 2G) or in response to stem cell factor (SCF) stimu-
lation in vitro (Online Supplementary Figure S3). mTOR defi-
ciency in Lin– or LSK cells resulted in a marked increase in
cell cycle-promoting Myc and E2F1 and a downregulation
of the cell cycle suppressor Rb (Figure 2G and H). In addi-
tion, increased basal activity of Akt and higher levels of
Bcl-xL and Mcl-1 were evident in mTOR–/– Lin– or LSK cells
(Figure 2G and H). The increased Akt phosphorylation in
these cells may be ascribable to the absence of the well-
documented S6K-mediated inhibitory feedback.11,12 These
results indicate that mTOR is involved in balanced signal-
ing of stem and progenitor cell survival and proliferation,
and is required for maintaining HSC quiescence. 
Because Mx1-cre expression is not restricted in
hematopoietic cells, the observed HSC phenotypes in
mTOR–/– mice could be due to a perturbed BM microenvi-
ronment. To overcome this caveat, we transplanted
mTORloxp/loxp;Mx1–Cre+ or control mTORloxp/loxp;Mx1-
Cre- BM cells into lethally irradiated BoyJ congenic mice
and induced mTOR deletion in blood lineages two
months after engraftment (Online Supplementary Figure
S4A). The mTOR–/– recipient mice phenocopied primary
mice showing an increase in total, CD34– and CD34+ LSK
cell numbers and a decrease in myeloid cells, erythrocytes,
and B cells in the BM and T cells in thymus compared to
mTOR+/+ recipient mice (Online Supplementary Figure S4B-
F), indicating that mTOR plays a cell autologous role in
mTOR in hematopoiesis  
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Figure 1. mTOR deficiency causes impaired hematopoiesis. (A) Western blotting of mTOR protein (left) and PCR
genotyping mTOR loxP and knockout (KO) alleles (right) in bone marrow (BM) cells. The Mx1-Cre allele was also
genotyped. (B) Blood count parameters. WBC: white blood cell; NE: neutrophil; LY: lymphocyte; MO: monocyte; RBC:
red blood cell; PLT: platelet; Hb: hemoglobin. (C) Total number of BM cells (left) and hematoxylin and eosin staining
of bone sections (right). (D) The number of myeloid cells (Gr1+Mac1+) in BM. (E) The numbers of erythroid lineages
in BM were quantified by FACS. Erythroid cells at different developmental stages include proerythroblasts
(Ter119med CD71hi), basophilic erythroblasts (Ter119hiCD71hi), late basophilic and chromatophilic erythroblasts
(Ter119hiCD71med), and orthochromatophilic erythroblasts (Ter119hiCD71lo). (F) The numbers of B-cell lineage in BM
were analyzed by FACS. B cells at different developmental stages include preB/proB (B220loIgM-), immature B
(B220loIgM+), and mature B(B220hiIgM+). (G) The numbers of T-cell lineage in thymus were analyzed by FACS. (H-J)
The percentages of apoptotic myeloid cells (H), erythrocytes (I) and B cells (J) were analyzed by Annexin V staining.
(K) Western blotting of Mcl-1 and Bcl-xL in lineage positive (Lin+) BM cells. Mouse number for each group n=5.
*P<0.05; **P<0.01. Error bars represent mean ± s.d.
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maintaining HSC and early progenitor homeostasis and
hematopoiesis.
mTOR regulates HSC and HPC repopulating potential 
To further examine the role of mTOR in stem cell regu-
lation, we next determined the impact of mTOR deficien-
cy on HSC repopulating capability. In a non-competitive
setting, mTOR deletion was induced before BM transplan-
tation into immunodeficient NOD/SCID mice (Figure 3A).
The mTOR loss caused a decrease in H2Kb+ donor-derived
cells in the BM and peripheral blood 30 days after trans-
plantation (Figure 3A and Online Supplementary Figure
S5A). In a competitive setting, mTOR deletion was
induced either before (Figure 3B) or after (Figure 3C) trans-
plantation of donor cells with recipient competitor cells
into congenic mice. A progressive decrease in CD45.2+
donor-derived cells was detected in the peripheral blood in
mTOR-/- recipient mice ((Figure 3B and C and Online
Supplementary Figure S5B). Similarly, the mTOR–/– CD45.2+
LSK cells were significantly reduced 30 days after pIpC
induction compared to mTOR+/+ controls (Figure 3C and
Online Supplementary Figure S5C). Therefore, mTOR defi-
ciency causes defective engraftment and hematopoietic
repopulation of stem/progenitor cells in transplantation
models. 
Discussion
In this study, we have found that mTOR knockout mice
develop BM failure due to impaired HSC homeostasis,
engraftment, and differentiation. mTOR deficiency drives
HSCs from quiescence into rapid cycling and transiently
increases HSC number. Such a transient increase in HSCs
associated with a loss of quiescence may lead to their
long-term exhaustion.6-8 Indeed, mTOR deficiency results
in a depletion of HSCs over time in competitively trans-
planted mice. Whether increased cycling of the stem cells
causes a decline and exhaustion of the HSCs in primary
mTOR–/– mice is difficult to determine due to the rapid
death of the animal. Interestingly, mTOR deficiency causes
certain hematopoietic phenotypes similar to that of TSC1
or PTEN deletion that causes mTOR activation, suggesting
that a tightly regulated mTOR activity is required for HSC
maintenance and hematopoiesis. mTOR deficiency causes
reduced engraftment, which differs from a recent report
that addition of the mTOR inhibitor, rapamycin, to a
cytokine cocktail of SCF, TPO and FL enhances the
engraftment of human CD34+ cord blood cells into NSG
mice.13 Such a discrepancy highlights the need for careful
examinations of genetic models that may be helpful in
revealing differences in effects between drug targets such
as mTOR and chemical inhibitors that may not be specific
to a target or may affect only a part of the target path-
F. Guo et al.
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Figure 2. Deletion of mTOR affects HSC and HPC home-
ostasis. (A) The numbers of common myeloid progenitors
(CMPs) (Lin-Sca1-c-Kit+CD34+CD16/CD32mid), granulocyte-
macrophage progenitors (GMPs) (Lin-Sca1-c-Kit+CD34+
CD16/CD32hi), megakaryocyte-erythroid progenitors
(MEPs) (Lin-Sca1-c-Kit+CD34-CD16/CD32lo), and common
lymphoid progenitors (CLP) (Lin-IL7R+Sca1medc-Kitmed-hi) in
bone marrow (BM) were analyzed by FACS. (B) The colony-
forming activities of CFU-E, CFU-C and BFU-E were exam-
ined using the total BM cells. (C) The numbers ofLSK (Lin-
scal+c-kit+), CD34-LSK, CD34+LSK, and CD150+CD41-CD48-
LSK cells in BM were analyzed by FACS. (D) Cell cycle pro-
file of LSK cells. LSK cells were labeled with BrdU in vivo, followed by BrdU and 7-AAD staining and FACS analysis (G0/G1:BrdU-7-AADlo;
S:BrdU+; G2/M:BrdU-7-AADhi). (E) The percentages of LSK progenitor cells and CD150+CD41-CD48-LSK stem cells in G0 phase (pyronin Y-
Hoechst 33342lo) of cell cycle were determined. (F) The percentage of apoptotic LSK cells was analyzed by Annexin V staining. (G) Western
blot analysis of the signaling activities in Lin- cells. (H) Quantitative RT-PCR analysis of LSK cells for the expression of indicated genes. n=3-



























































































































































































































ways. mTOR signals through two parallel molecular com-
plexes: mTOR complex 1 ( mTORC1) and mTORC2.1
Most of the hematopoietic phenotypes in mTOR-defi-
cient mice recapitulate that of Raptor, an essential compo-
nent of mTORC1, deficient mice. For instance, both
mTOR deficiency and Raptor deficiency cause loss of qui-
escence and increased cell cycling of HSCs, without affect-
ing their survival status.14,15 In line with recent reports that
ablation of mTORC2 component Rictor has negligible
effects on the majority of hematopoietic cells,16-18 mTOR
appears to function in HSCs and hematopoietic lineage
development dependent of mTORC1, but not of
mTORC2. One exception is that mTOR regulation of T-
lymphocyte development requires both mTORC1 and
mTORC2, because deletion of either Raptor (data not
shown) or Rictor impairs thymocyte differentiation.16,17
Interestingly, while mTOR deficiency causes a reduction in
myeloid cells, these cells are increased in Raptor–/– or
Raptor–/–; Rictor–/–mice.14 Thus, mTOR may act in a way that
is not strictly dependent on mTORC1 and mTORC2 in
myeloid cells. In support of this, we have found that
mTOR regulates FANCD2, a key component of Fanconi
anemia DNA repair pathway, and genomic stability inde-
pendent of mTORC1 or mTORC2 in HSCs.19 Similarly,
mTOR deficiency in muscle cells more severely affects
muscle contractile properties and reduces dystrophin
expression compared to Raptor–/–, Rictor–/–, or Raptor–/–;
Rictor–/– mice.11 Furthermore, mTOR knockdown by RNAi
represses translation efficiency of terminal oligopyrimi-
dine mRNA, whereas Raptor or Rictor deficiency has only
a marginal effect on terminal oligopyrimidine mRNA
translation.20 Thus, it is likely that mTOR functions
through mTORC1 and/or mTORC2 is contingent upon
cell type and physiological context.
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Figure 3. mTOR deficiency causes an impaired repopulating potential of HSCs. (A) Left: schematics of donor transplantation into NOD-SCID
mice. Right: bone marrow (BM) cells from pIpC-treated donor mice were transplanted into sub-lethally irradiated NOD/SCID mice. The donor-
derived cells in BM and peripheral blood (PB) of recipient mice were analyzed identified by H2-Kb+ staining. (B) Left hand side: schematics of
competitive donor transplantation into syngeneic BoyJ mice. Right: BM cells from pIpC-treated donor mice (C57Bl/6) were mixed at 1:1 ratio
with BM cells from BoyJ recipient mice. The cell mixtures were transplanted into lethally irradiated BoyJ rmice. The donor-derived cells were
identified by CD45.2+ staining. (C) Left: schematics of competitive donor transplantation into syngeneic BoyJ mice. Middle and right: BM cells
from donor mice were mixed at 7:3 ratio with BM cells from BoyJ recipient mice. The cell mixtures were transplanted into lethally irradiated
BoyJ mice. The recipient mice were injected with pIpC 2 months post transplantation. The percentage of overall donor-derived cells in PB of
the recipient mice were analyzed at various days post pIpC induction by CD45.2 staining (middle). The percentage of donor-derived LSK cells
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